SRR8518239
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.430
- OXIDATIVE_PHOSPHORYLATION+0.280
- MITOTIC_SPINDLE+0.260
- SPERMATOGENESIS+0.250
- DNA_REPAIR+0.210
- MTORC1_SIGNALING+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- INTERFERON_GAMMA_RESPONSE-0.550
- INFLAMMATORY_RESPONSE-0.480
- COMPLEMENT-0.430
- TNFA_SIGNALING_VIA_NFKB-0.420
- ALLOGRAFT_REJECTION-0.410
- IL6_JAK_STAT3_SIGNALING-0.410
- ANGIOGENESIS-0.400
- COAGULATION-0.370
- IL2_STAT5_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518295 | — | E | 0.955 |
| 2 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.937 |
| 3 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.935 |
| 4 | ERR2208894 | — | — | 0.927 |
| 5 | TCGA-A1-A0SO-01A-22R-A084-07 | — | E | 0.924 |
| 6 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.924 |
| 7 | SRR8518240 | — | E | 0.921 |
| 8 | SRR3147738 | — | — | 0.920 |
| 9 | MNG704 | — | — | 0.918 |
| 10 | SRR1313140 | — | E | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |